<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2609222644
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIRTAZA 30 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MIRTAZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- What MIRTAZA is:</strong><br />Depression is longer lasting or more severe than the &quot;low moods&quot; everyone has from time to time due to the stress of everyday life. &nbsp;It is thought to be caused by a chemical imbalance in parts of the brain. &nbsp;This affects your whole body and can cause emotional and physical symptoms, such as feeling low in spirit, loss of interest in activities, unable to enjoy life, poor appetite or overeating, disturbed sleep, often waking up early, loss of sex drive, lack of energy and feeling guilty over nothing. &nbsp;Mirtazapine corrects this chemical imbalance and may help relieve the symptoms of depression. There is no evidence that this medicine is addictive.</p><p>&nbsp;</p><p><strong>b- What it is taken for:</strong><br />The name of your medicine is MIRTAZA. It contains the active ingredient mirtazapine. It is used to treat depression. Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason. This medicine is available only with a doctor&#39;s prescription.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- Do not take MIRTAZA:</strong><br />Do not take this medicine if you have or have had any of the following:<br />- The expiry date (EXP) printed on the pack has passed.</p><p>- The packaging is torn, shows signs of tampering or it does not look quite right.</p><p>- You have had an allergic reaction to mirtazapine or any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include cough, shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, throat or other parts of the body, rash, itching or hives on the skin; fainting or hayfever-like symptoms</p><p>- If you think you are having an allergic reaction, do not take any more of the medicine and contact your doctor immediately or go to the Accident and Emergency department at the nearest hospital.</p><p>- If you are taking other medicines called Monoamine Oxidase Inhibitors (MAOIs). MAOIs may be used for the treatment of depression (phenelzine, tranylcypromine, moclobemide), Parkinson&#39;s disease (selegiline), infections (linezolid), or diagnosis of certain conditions/treatment of certain blood disorders (methylene blue). There may be other MAOIs also so check with your doctor or pharmacist.</p><p>- Do not take mirtazapine until 14 days after stopping any MAOI, and do not take MAOIs until 14 days after stopping mirtazapine. Taking this medicine with a MAOI may cause a serious reaction with a sudden increase in body temperature, extremely high blood pressure and severe convulsions. Ask your doctor or pharmacist if you are not sure if you have been taking a MAOI medicine.</p><p>- Do not give mirtazapine to a child or adolescent. The safety and efficacy of this medicine in patients under 18 years has not been established.</p><p>&nbsp;</p><p><strong>b- Take special care with MIRTAZA:</strong><br />Before you start taking this medicine, tell your doctor if:</p><p>- You have allergies to any other medicines any other substances, such as foods, preservatives or dyes.<br />&nbsp; &nbsp;These tablets contain lactose.</p><p>- You have or have had any medical conditions, especially the following:</p><ul><li>thoughts of suicide or self-harm</li><li>epilepsy (fits or convulsions)</li><li>liver problems, such as jaundice</li><li>kidney problems</li><li>heart problems</li><li>low blood pressure</li><li>any mental illness (e.g. schizophrenia, bipolar disorder)</li><li>diabetes</li><li>glaucoma (increased pressure in the eyes)</li><li>difficulties in urination as a result of an enlarged prostate</li><li>unexplained high fever, sore throat and mouth ulcers</li><li>fructose intolerance</li><li>glucose-galactose malabsorption</li><li>low sodium levels in your blood (hyponatraemia).</li></ul><p>- You are planning to have surgery or an anaesthetic.<br />- You are currently receiving or are planning to receive dental treatment.</p><p>- You are taking or are planning to take any other medicines, This includes vitamins and supplements that are available from your pharmacy, supermarket or health food shop.</p><p>- Do not give this medicine to anyone else, even if their symptoms seem similar to yours.</p><p>- Do not take your medicine to treat any other condition unless your doctor or pharmacist tells you to</p><p>- Do not stop taking your medicine suddenly, or change the dosage, without first checking with your doctor. Stopping your&nbsp;medicine suddenly may cause nausea, headache, dizziness, anxiety or agitation. Your doctor may want to gradually reduce the amount of medicine you are taking before stopping completely.</p><p>&nbsp;</p><p><strong>c- Taking MIRTAZA with other medicines, herbal or dietary supplements:</strong><br />Some medicines may interact with mirtazapine. These include:</p><p>&bull; other medicines for depression (e.g. SSRIs, venlafaxine, nefazodone), anxiety, obsessive compulsive disorders or pre-menstrual dysphoric disorder<br />&bull; MAOIs (such as phenelzine, tranylcypromine, moclobemide, linezolid, methylene blue and selegiline)<br />&bull; medicines to help you sleep or calm down (e.g. benzodiazepines and other sedatives or tranquillisers)<br />&bull; medicines containing St. John&#39;s Wort (hypericum perforatum)<br />&bull; phenytoin or carbamazepine, medicines used to treat epilepsy<br />&bull; warfarin, a medicine used to prevent blood clotting<br />&bull; erythromycin, an antibiotic<br />&bull; rifampicin, a medicine used to treat tuberculosis<br />&bull; medicines to treat fungal infections, such as ketoconazole<br />&bull; HIV/AIDS medicines<br />&bull; cimetidine, a medicine used to treat reflux or stomach ulcers<br />&bull; medicines to treat migraine attacks, such as sumatriptan, naratriptan and zolmitriptan<br />&bull; tramadol, a strong painkiller<br />&bull; medicines which may cause your body to gain fluid.<br />&bull; tryptophan, found in some preparations bought in health food shops</p><p>If you are taking any of these you may need a different dose or you may need to take different medicines. Other medicines not listed above may also interact with mirtazapine.</p><p>Taking MIRTAZA with alcohol can make you more sleepy and less alert. Your doctor may suggest you avoid alcohol while being treated with this medicine.</p><p>&nbsp;</p><p><strong>d- Taking MIRTAZA with food and drink:&nbsp;</strong><br />It does not matter if you take MIRTAZA before, with or after food.</p><p>&nbsp;</p><p><strong>e- Pregnancy and breast-feeding:</strong><br />- If you are currently pregnant or you plan to become pregnant. Do not take this medicine whilst pregnant until you and your doctor have discussed the risks and benefits involved.</p><p>- If you are currently breast-feeding or you plan to breast-feed. Do not take this medicine whilst breast-feeding until you and your doctor have discussed the risks and benefits involved.</p><p>&nbsp;</p><p><strong>f- Driving and using machines:</strong><br />Be careful when driving or operating machinery until you know how this medicine affects you. This medicine may cause drowsiness, sleepiness or dizziness in some people and affect alertness and concentration. &nbsp;If any of these occur, do not drive, operate machinery or do anything else that could be dangerous.</p><p>&nbsp;</p><p><strong>g- Important information about some of the ingredients of MIRTAZA:</strong><br />This medicine contains lactose, if you are intolerant to lactose and if you think you are having an allergic reaction, do not take any more of the medicine and contact your doctor immediately or go to the Accident and Emergency department at the nearest hospital.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow carefully all directions given to you by your doctor or pharmacist. Their instructions may be different to the information in this leaflet.</p><p><strong>a- How much MIRTAZA to take:</strong><br />Your doctor or pharmacist will tell you how much of this medicine you should take. This will depend on your condition and whether you are taking any other medicines. The usual starting dose is 15 mg per day. &nbsp;Your doctor may slowly increase your dose depending on how you respond to mirtazapine. The effective dose for most people is usually between 30 mg and 45 mg per day. Do not stop taking your medicine or change your dosage without first checking with your doctor.</p><p>&nbsp;</p><p><strong>b- How and When to take MIRTAZA:</strong><br />Swallow the tablet(s), without chewing, together with some water or other fluid. This medicine should preferably be taken as a single night-time dose before going to bed. &nbsp;If recommended by your doctor, your dose may be taken in sub-doses equally divided over the day (e.g. once in the morning and once at night-time before going to bed). Take this medicine at the same time or times each day. Taking it at the same time each day will have the best effect and will also help you remember when to take it. It does not matter if you take it before, with or after food. Continue taking your medicine for as long as your doctor tells you. For depression, the length of treatment will depend on how quickly your symptoms improve. &nbsp;Most antidepressants take time to work, so do not be discouraged if you don&#39;t feel better right away.</p><p>Some of your symptoms may improve in 1-2 weeks, but it can take up to 2-4 weeks to feel the full benefit of the medicine. Even when you feel well, you will usually have to take your medicine for 4-6 months, or even longer, to make sure the benefits will last. Make sure you have enough to last over weekends and holidays.</p><p>&nbsp;</p><p><strong>c- If you take more MIRTAZA than should:</strong><br />If you think that you or anyone else may have taken too much of this medicine, immediately telephone your doctor or the Poisons Information Centre for advice. Alternatively go to the Accident and Emergency Department at your nearest hospital. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention. If you take too much mirtazapine you may feel drowsy, dizzy, confused, agitated, have increased heart rate or lose consciousness.<br />&nbsp;<br /><strong>d- If you forget to take MIRTAZA:</strong></p><p><strong>Once-Daily Dosing:</strong><br />If you forget to take your dose before going to bed, do not take the missed dose the next morning, because it may cause drowsiness or sleepiness during the day. &nbsp;Wait until the next evening before taking your normal dose. Do not take a double dose to make up for the missed dose.&nbsp;</p><p><strong>Twice-Daily Dosing:</strong><br />If you forget your morning dose, simply take it together with your evening dose.</p><p>If you forget your evening dose, do not take it with the next morning dose. &nbsp;Skip the missed dose and continue treatment with your normal morning and evening doses.</p><p>If you have forgotten both doses, you should not make up for the missed doses; the next day, just continue with your normal morning and evening doses.</p><p>If you have trouble remembering to take your medicine, ask your pharmacist for some hints to help you remember.</p><p>&nbsp;</p><p><strong>e- While you are taking MIRTAZA:</strong><br />Tell your doctor that you are taking this medicine if:</p><p>- you are about to be started on any new medicine</p><p>- you are pregnant or are planning to become pregnant. Tell your doctor immediately, however do not stop taking your medicine until you have spoken to your doctor. When taken during pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.</p><p>- you are breast-feeding or are planning to breast-feed. It is not known if mirtazapine passes into breast milk, Your doctor will discuss with you the risks and benefits of taking this medicine whilst breast-feeding.</p><p>- you are about to have any blood tests.</p><p>- you are going to have surgery or an anaesthetic or &nbsp;are going into hospital. Your doctor may occasionally do tests to make sure the medicine is working and to prevent side effects. Go to your doctor regularly for a check-up. Tell your doctor immediately if you develop fever, chills, sore throat or mouth ulcers or experience other signs of infections.</p><p>- In rare cases mirtazapine can cause a shortage of white blood cells, resulting in lowering body resistance to infection. &nbsp;These symptoms may appear after 2-6 weeks of treatment.</p><p>- Tell your doctor immediately or go to the nearest hospital for treatment if you have any suicidal thoughts or other mental/mood changes. Young adults aged 18 to 24 are at particularly high risk of having this happen to them.</p><p>- Occasionally, the symptoms of depression or other psychiatric conditions may include thoughts of harming yourself or committing suicide. Until the full antidepressant effect of the medicine becomes apparent, it is possible that these symptoms may increase in the first few weeks of treatment.</p><p>- If you or someone you know is demonstrating any of the following warning signs of suicide while taking this medicine, contact your doctor or health professional immediately or go to the nearest hospital for treatment:</p><p>&bull; thoughts or talk of death or suicide<br />&bull; thoughts or talk of self-harm or harm to others<br />&bull; any recent attempts to self-harm<br />&bull; increase in aggressive behaviour, irritability or agitation.<br />&bull; All mention of suicide or violence must be taken seriously.</p><p>- If you have diabetes take care to monitor your blood sugar levels. Your diabetes medication may need to be adjusted.</p><p>- Tell your doctor if, for any reason, you have not taken your medicine exactly as prescribed. Otherwise your doctor may think that it was not effective and change your treatment unnecessarily. Tell your doctor if you feel this medicine is not helping your condition. Tell any other doctors, dentists and pharmacists who are treating you that you take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking mirtazapine or if you have any&nbsp;questions or concerns. Do not be alarmed by the following lists of side effects. You may not experience any of them. All medicines can have side effects. Sometimes they are serious but most of the time they are not.</p><p>Tell your doctor or pharmacist if you notice any of the following and they worry you. This list includes the more common side effects. Mostly, these are mild:</p><p>&bull; drowsiness or sleepiness&nbsp;<br />&bull; headache<br />&bull; tiredness, feeling weak<br />&bull; increase in appetite, weight gain&nbsp;<br />&bull; dry mouth<br />&bull; diarrhoea<br />&bull; occasional dizziness or faintness, especially when you get up quickly from a lying or sitting position&nbsp;<br />&bull; swollen ankles or feet as a result of fluid accumulation (oedema)&nbsp;<br />&bull; fluid retention with weight gain<br />&bull; mild rash&nbsp;<br />&bull; nightmares/vivid dreams&nbsp;<br />&bull; tingling fingers or toes<br />&bull; painful joints<br />&bull; muscle aches and pains&nbsp;<br />&bull; restless legs&nbsp;</p><p>&nbsp;</p><p>Tell your doctor as soon as possible if you notice any of the following. These may be serious side effects. You may need medical attention. Most of these side effects are rare.</p><p>&bull; itching or any type of skin rash or blistering, peeling or flaking skin<br />&bull; low sodium levels (feeling weak, sick, confused, exhausted, with muscle weakness or cramps)<br />&bull; feeling agitated, anxious or irritable&nbsp;<br />&bull; feeling extremely restless and having an overwhelming urge to always be moving<br />&bull; unable to walk properly<br />&bull; numbness in the mouth<br />&bull; unable to sleep or stay asleep*<br />&bull; unusual changes in behaviour<br />&bull; shaking or tremors<br />&bull; generalised fluid retention with weight gain<br />&bull; fever, sore throat, mouth ulcers, gastrointestinal (stomach, bowels) disturbances<br />&bull; eye pain (a possible sign of glaucoma or raised pressure in the eye)<br />* may be symptoms of depression.</p><p>&nbsp;</p><p>If you experience any of the following, stop taking your medicine and contact your doctor immediately or go to the Accident and Emergency department at your nearest hospital. These are very serious side effects and are usually very rare. You may need urgent medical attention or hospitalisation.</p><p>&bull; thoughts or actions relating to suicide or self-harm<br />&bull; severe skin reaction which starts with painful red areas, then large blisters and ends with peeling of layers of skin. This may be accompanied by fever and chills, aching muscles and generally feeling unwell.<br />&bull; chest pain, fast or irregular heartbeat.<br />&bull; epilepsy or fits (seizures)<br />&bull; shaking or tremors<br />&bull; sudden muscle contractions (myoclonus)<br />&bull; fainting, cough and problems breathing (signs of a blood clot on the lung)<br />&bull; attack of excessive excitability (mania)<br />&bull; confusion<br />&bull; hallucinations (hearing, seeing or feeling things that are not there)<br />&bull; yellow colouring of eyes or skin; this may suggest problems with your liver<br />&bull; fever, sweating, increased heart rate, uncontrollable diarrhoea, muscle contractions, shivering, overactive reflexes, restlessness, mood changes and unconsciousness (serotonin syndrome).</p><p>&nbsp;</p><p>Other side effects not listed above may occur in some patients. &nbsp;Some side effects may occur with no symptoms, and may only be identified by tests. For example, high blood pressure, high cholesterol or fat levels, changes in levels of white or red blood cells.</p><p><strong>Allergic reactions</strong><br />If you think you are having an allergic reaction to mirtazapine, do not take any more of this medicine and tell your doctor immediately or go to the Accident and Emergency department at your nearest hospital.<br />Symptoms of an allergic reaction may include some or all of the following:</p><p>&bull; cough, shortness of breath, wheezing or difficulty breathing.<br />&bull; swelling of the face, lips, tongue, &nbsp;throat or other parts of the body<br />&bull; rash, itching or hives on the skin<br />&bull; fainting<br />&bull; hayfever-like symptoms</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine where children cannot reach it.</p><p>- A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.</p><p>- Keep your medicine in its original packaging until it is time to take it.</p><p>- If you take your medicine out of its original packaging it may not keep well.<br />- Keep your medicine in a cool dry place below 30&deg;C.</p><p>- Do not store your medicine, or any other medicine, in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.</p><p>- Disposal: If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- What the medicinal ingredient is:</strong><br />The active substance is mirtazapine</p><p>&nbsp;</p><p><strong>b- What the non-medicinal ingredients are:</strong><br />The other ingredients are lactose, cellulose microcrystalline, croscarmellose sodium, magnesium stearate, hypromellose, hydroxypropylcellulose, macrogol 8000, titanium dioxide, iron oxide red CI 77491 (30 mg only), iron oxide yellow CI 77492 (15 mg and 30 mg).</p><p>This medicine is gluten-free, sucrose-free, tartrazine-free and free of other azo dyes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                15 mg tablets
Pale Yellow, oval shaped, scored, film coated tablets, imprinted "APO" on one side and "MI" bisect "15" on the other side.
Available in blister packs of 30 tablets (3 blisters of 10 tablets each).

30 mg tablets
Light pink, oval shaped, scored, film coated tablets, imprinted "APO" on one side and "MI" bisect "30" on the other side.
Available in blister packs of 30 tablets (3 blisters of 10 tablets each).

45 mg tablets
White to off-white, oval shaped, unscored, film coated tablets, imprinted "APO" on one side and "MI-45" on the other side.
Available in blister packs of 30 tablets (3 blisters of 10 tablets each).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Apotex Incorporated<br />150 Signet Drive<br />Toronto, Ontario<br />Canada, M9L 1T9<br />Tel: 1-800-268-4623, Fax: 1-800-609-9444<br />www.apotex.com</p><p><strong>Manufacturer</strong><br />Apotex Incorporated<br />50 Steinway Boulevard<br />Etobicoke, Ontario<br />Canada, M9W 6Y3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised 06/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>أ- ما هو ميرتازا:</strong><br />يعد الاكتئاب حالة أكثر شدة وتدوم لوقت أطول من حالة &quot;قلة المزاج&quot; التي تحدث لجميع الأشخاص من وقت لآخر بسبب التوتر في الحياة اليومية. &nbsp;ويرجح أن الاكتئاب ينتج عن اختلال التوازن الكيميائي في أجزاء من الدماغ. &nbsp;يؤثر ذلك على الجسم بالكامل ويمكن أن يسبب أعراضًا انفعالية وجسدية، مثل الشعور بهبوط الروح، فقد الاهتمام بالأنشطة، عدم القدرة على الاستمتاع بالحياة، ضعف الشهية أو فرط الأكل، اضطراب النوم، كثرة الاستيقاظ في وقت مبكر، فقد الرغبة الجنسية، نقص الطاقة والشعور بالذنب دون سبب. &nbsp;يعمل ميرتازابين على تصحيح اختلال التوازن الكيميائي ويمكن أن يساعد في تخفيف أعراض الاكتئاب. ليس هناك دليل على أن هذا الدواء يسبب الإدمان.</p><p>&nbsp;</p><p><strong>ب- في ماذا يستعمل هذا الدواء:</strong><br />يسمى هذا الدواء أبو-ميرتازابين. يحتوي الدواء على المادة الفعالة ميرتازابين ويستخدم لعلاج الاكتئاب. إذا كانت لديك أي استفسارات عن سبب استخدام هذا الدواء، فتوجه بها إلى طبيبك. قد يكون طبيبك قد وصف لك هذا الدواء لسبب آخر. هذا الدواء متوفر فقط بناءً على وصفة طبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- لا تستخدم ميرتازا:</strong><br />لا تتناول هذا الدواء إذا كنت مصابًا أو أصبت في وقت سابق أو لاحظت ما يلي:<br />- بعد انتهاء تاريخ انتهاء الصلاحية المدون على العبوة.</p><p>- تمزق العبوة أو ظهور علامات العبث أو إذا لم تبدُ العبوة سليمة تمامًا.&nbsp;</p><p>- أصبت بتفاعل حساسية لميتازابين أو أي من المكونات المدرجة في نهاية هذه النشرة. تتضمن أعراض تفاعل الحساسية ما يلي: الكحة، ضيق التنفس، الصفير أو صعوبة التنفس، تورم الوجه أو الشفتين أو اللسان أو الحلق أو أجزاء أخرى في الجسم، الطفح، الحكة أو الشرى على الجلد، الإغماء أو الأعراض الشبيهة بحمى الكلأ.</p><p>- إذا كنت تعتقد أنك تعاني من تفاعل حساسية، &nbsp;لا تتناول أي جرعة أخرى من الدواء واتصل بطبيبك على الفور أو توجه إلى قسم الحوادث والطوارئ في أقرب مستشفى.</p><p>- لا تتناول هذا الدواء إذا كنت تتناول أدوية أخرى يطلق عليها مثبطات المونو أمين أكسيداز (MAOIs). يمكن استخدام مثبطات المونو أمين أكسيداز في علاج الاكتئاب (فينيلزين، ترانيلسيبرومين، موكلويبمايد)، أو داء باركنسون (سيليجيلين)، أو العدوى (لينيزوليد)، أو في تشخيص بعض الحالات/علاج اضطرابات معينة في الدم (ميثيلين بلو). هناك أيضًا أمثلة أخرى على مثبطات المونو أمين أكسيداز، لذا تحقق من طبيبك أو الصيدلي.</p><p>- لا تتناول ميرتازابين قبل مرور 14 يومًا على وقف تناول أي دواء من مثبطات المونو أمين أكسيداز، ولا تتناول أي دواء من مثبطات المونو أمين أكسيداز قبل مرور 14 يومًا على وقف تناول ميرتازابين . تناول هذا الدواء مع مثبطات المونو أمين أكسيداز يمكن أن يسبب تفاعلاً خطيرًا مع زيادة مفاجئة في درجة حرارة الجسم وارتفاع مفرط في ضغط الدم وتشنجات شديدة. اسأل طبيبك أو الصيدلي إذا لم تكن متأكدًا من كونك تتناول أحد مثبطات المونو أمين أكسيداز.&nbsp;</p><p>- لا تعطِ ميرتازابين لطفل أو مراهق. لم تتم دراسة الأمان والفعالية لهذا الدواء في المرضى الأقل من 18 عامًا.</p><p>&nbsp;</p><p><strong>ب- الاحتياطات عند الاستعمال:</strong></p><p><strong>قبل أن تبدأ في تناول هذا الدواء، أخبر طبيبك إذا:</strong><br />- كنت تعاني من حساسية لأي أدوية أخرى أو أي مواد أخرى، مثل الأطعمة أو المواد الحافظة أو الأصباغ. تحتوي هذه الأقراص على اللاكتوز.</p><p>- كنت مصابًا أو أصبت في وقت سابق بأي حالة طبية، وخاصة ما يلي:<br />&bull; أفكار بالانتحار أو إيذاء النفس<br />&bull; الصرع (نوبات أو تشنجات)<br />&bull; مشاكل في الكبد، مثل اليرقان<br />&bull; مشاكل في الكلى<br />&bull; مشاكل في القلب<br />&bull; انخفاض ضغط الدم<br />&bull; أي مرض عقلي (مثل الشيزوفرينيا، الاضطراب ثنائي القطب)<br />&bull; السكري<br />&bull; الجلوكوما (ارتفاع الضغط داخل العين)<br />&bull; صعوبة في التبول نتيجة لتضخم البروستاتا<br />&bull; حمى شديدة و التهاب في الحلق وقرح في الفم غير معروفي السبب<br />&bull; عدم تحمل الفركتوز<br />&bull; سوء امتصاص الجلوكوز-الجلاكتوز<br />&bull; انخفاض مستويات الصوديوم في الدم<br />- كنت تخطط للخضوع لجراحة أو تخدير.</p><p>- كنت تتلقى في الوقت الحالي أو تخطط لتلقي علاج خاص بالأسنان.</p><p>- تتناول أو تخطط لتناول أي أدوية أخرى، ويتضمن ذلك الفيتامينات والمكملات المتوفرة في الصيدلية أو السوبر ماركت أو متجر الطعام الصحي.</p><p>- لا تحاول إعطاء هذا الدواء لأي شخص آخر، حتى إذا كانت الأعراض لديه مشابهة للأعراض لديك.</p><p>- لا تحاول تناول الدواء لعلاج أي حالة أخرى ما لم يطلب منك طبيبك أو الصيدلي ذلك.</p><p>- لا تقم بوقف تناول الدواء فجأة أو تغيير الجرعة بدون استشارة الطبيب أولاً. وقف تناول الدواء فجأة قد يسبب غثيان، أو صداع، أو دوار، أو قلق، أو هياج. قد يرغب طبيبك في تقليل كمية الدواء التي تتناولها بشكل تدريجي قبل وقف تناول الدواء بالكامل.</p><p>&nbsp;</p><p><strong>ت- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية:</strong></p><p>بعض الأدوية قد تتفاعل مع ميرتازابين. وتضم هذه الأدوية ما يلي:<br />&bull; الأدوية الأخرى لعلاج الاكتئاب (مثل مثبطات استرجاع السيروتونين الانتقائية، فينلافاكسين، نيفازودون) أو القلق أو &nbsp;اضطراب الوسواس القهري أو اضطراب ما قبل الحيض<br />&bull; مثبطات المونو أمين أكسيداز (مثل فينيلزين، ترانيلسيبرومين، موكلوبيمايد، لينيزوليد، ميثيلين بلو، سيليجيلين)<br />&bull; المنومات أو المهدئات (مثل البنزوديازيبين أو المهدئات أو المسكنات الأخرى)<br />&bull; الأدوية التي تحتوي على نبتة سانت جونز (حشيشة القلب أو hypericum perforatum)<br />&bull; الفينيتوين أو كاربامازيبين، وهي أدوية تستخدم لعلاج الصرع<br />&bull; الوارفارين، وهو دواء يستخدم لمنع تجلط الدم<br />&bull; إريثرومايسين، وهو مضاد حيوي<br />&bull; ريفامبيسين، وهو دواء لعلاج الدرن<br />&bull; الأدوية التي تستخدم في علاج العدوى الفطرية، مثل كيتوكونازول<br />&bull; أدوية فيروس نقص المناعة البشرية/الإيدز<br />&bull; سيميتيدين، وهو دواء يستخدم لعلاج الارتجاع أو قرح المعدة<br />&bull; الأدوية التي تستخدم في علاج نوبات الصداع النصفي، مثل سوماتريبتان وناراتريبتان وزولميتريبتان<br />&bull; الترامادول، وهو مسكن قوي للألم<br />&bull; الأدوية التي يمكن أن تسبب اكتساب الجسم للمياه.<br />&bull; تريبتوفان، ويوجد في بعض المنتجات التي يتم بيعها في متاجر الطعام الصحي</p><p>إذا كنت تتناول أيًا من هذه الأدوية، فقد تحتاج إلى تغيير الجرعة أو قد تحتاج إلى تناول أدوية مختلفة. قد تتفاعل أدوية أخرى غير مدرجة أعلاه مع ميرتازابين.</p><p>تناول هذا الدواء مع الكحول قد يجعلك أكثر نعاسًا وأقل انتباهًا. قد يقترح طبيبك تجنب تناول الكحول أثناء العلاج بهذا الدواء.</p><p>&nbsp;</p><p><strong>ث- استعمال ميرتازا مع الطعام والشراب:</strong><br />الطعام والشراب ليس لها تأثير ولا يهم ان تأخذ الدواء قبل أو بعد.</p><p>&nbsp;</p><p><strong>ج- الحمل والرضاعة:</strong><br />- إذا كنتي حاملاً في الوقت الحاضر أو كنتي تخططين للحمل. لا تتناولي هذا الدواء أثناء الحمل قبل أن تناقشي مع طبيبك المخاطر والفوائد التي ينطوي عليها.</p><p>- إذا كنتي ترضعين رضاعة طبيعية أو تخططين للإرضاع الطبيعي. لا تتناولي هذا الدواء أثناء الرضاعة قبل أن تناقشي مع طبيبك المخاطر والفوائد التي ينطوي عليها.</p><p>&nbsp;</p><p><strong>ح- تأثيره على القيادة واستخدام الآلات:</strong><br />توخَّ الحرص عند القيادة أو تشغيل الآلات حتى تعلم مدى تأثير هذا الدواء عليك. هذا الدواء قد يسبب لبعض الأشخاص النعاس أو الدوار ويؤثر على اليقظة والتركيز. إذا حدث أي مما سبق، لا تقم بقيادة السيارة أو تشغيل الآلات أو فعل أي شيء آخر قد يكون خطيرًا.</p><p>&nbsp;</p><p><strong>خ- معلومات هامة حول بعض المكونات:</strong><br />هذا الدواء يحتوي على اللاكتوز، فإذا كنت لا تتقبل اللاكتوز، وإذا كنت تعتقد أنك تواجه رد فعل تحسسي، لا تأخذ أي شيء من الدواء واتصل بطبيبك على الفور أو الذهاب إلى قسم الحوادث والطوارئ في أقرب مستشفى.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اتبع بدقة جميع إرشادات طبيبك أو الصيدلي. قد تختلف تعليمات الطبيب والصيدلي عن تلك المدرجة في هذه النشرة.</p><p>&nbsp;</p><p><strong>أ- ماهو المطلوب استخدامه من ميرتازا:</strong><br />سوف يخبرك طبيبك أو الصيدلي بالجرعة التي ينبغي عليك تناولها من هذا الدواء. سوف يعتمد ذلك على حالتك وما إذا كنت تتناول أي أدوية أخرى. جرعة البدء المعتادة هي 15 ملجم في اليوم. &nbsp;قد يقوم طبيبك بزيادة جرعتك ببطء بناءً على مدى استجابتك لميرتازابين. الجرعة الفعالة لمعظم الأشخاص عادة ما تكون بين 30 ملجم في اليوم و45 ملجم في اليوم. لا توقف تناول الدواء أو تغير جرعتك بدون استشارة طبيبك أولاً.</p><p>&nbsp;</p><p><strong>ب- كيف يستخدم ميرتازا و متى:</strong><br />ابلع القرص (الأقراص) دون مضغ مع الماء أو سائل آخر. يفضل تناول هذا الدواء كجرعة ليلية مفردة قبل النوم. إذا أوصى طبيبك بذلك، يمكن تناول الجرعة كجرعات مقسَّمة على مدار اليوم (مثال: مرة واحدة صباحًا ومرة واحدة قبل النوم). تناول هذا الدواء في نفس الوقت (أو الأوقات) يوميًا. تناول الدواء في نفس الموعد يوميًا يؤدي للحصول على أفضل تأثير، كما يساعدك على تذكر موعد تناوله. من غير المهم تناول الدواء مع الطعام أو بدونه. استمر في تناول الدواء طوال المدة التي يحددها لك الطبيب. بالنسبة للاكتئاب، يعتمد طول مدة العلاج على السرعة التي تتحسن بها الأعراض لديك. تستغرق معظم الأدوية المضادة للاكتئاب وقتًا لبدء العمل، لا تشعر بالإحباط إذا لم تشعر بتحسن على الفور.</p><p>&nbsp;</p><p>قد تتحسن بعض الأعراض لديك خلال 1-2 أسبوع، ولكن الأمر قد يستغرق حتى 2-4 أسابيع للشعور بالفائدة الكاملة للدواء. حتى إذا شعرت أنك على ما يرام، ينبغي عليك في العادة تناول الدواء لمدة 4-6 أشهر أو أكثر للتأكد من استمرار الفائدة منه. تأكد من وجود كمية من الدواء لديك تكفيك خلال العطلات الأسبوعية والأجازات.&nbsp;</p><p>&nbsp;</p><p><strong>ت- الجرعة الزائدة:</strong><br />إذا كنت تعتقد أنك أنت أو أي شخص آخر قد تناولت جرعة زائدة من هذا الدواء، قم على الفور بالاتصال بطبيبك أو بمركز معلومات السموم للاستشارة. يمكنك بدلاً من ذلك التوجه إلى قسم الحوادث والطوارئ في أقرب مستشفى. قم بذلك حتى إذا لم تكن هناك علامات مزعجة أو علامات تسمم. قد تحتاج للرعاية الطبية العاجلة. إذا تناولت جرعة زائدة من ميرتازابين فقد تشعر بالنعاس، أو الدوار، أو التشوش، أو الهياج، أو زيادة معدل ضربات القلب، أو فقد الوعي.</p><p>&nbsp;</p><p><strong>ث- الجرعة الفائتة:</strong></p><p><strong>مرة واحدة يوميًا:</strong><br />إذا نسيت تناول الجرعة قبل النوم، لاتتناول الجرعة الفائتة في الصباح، حيث أن هذا قد يسبب النعاس خلال النهار. انتظر حتى مساء اليوم التالي لتناول الجرعة المعتادة. لا تتناول جرعة مزدوجة لتعويض الجرعة الفائتة.&nbsp;</p><p><strong>مرتين يوميًا:</strong><br />إذا نسيت تناول جرعة النهار، فقم بتناولها مع جرعة المساء.<br />إذا نسيت تناول جرعة المساء، فلا تتناولها مع جرعة النهار في صباح اليوم التالي. &nbsp;تجاوز الجرعة الفائتة واستمر في العلاج بجرعة الصباح والمساء المعتادة.</p><p>إذا نسيت تناول كلتا الجرعتين، ينبغي عدم تعويض الجرع الفائتة. في اليوم التالي، استمر في تناول جرع الصباح والمساء المعتادة. إذا كانت لديك مشكلة في تذكر تناول الدواء، اطلب من الصيدلي بعض الملحوظات لمساعدتك على التذكر.</p><p>&nbsp;</p><p><strong>ح- عند استخدام ميرتازا:</strong></p><p><strong>أخبر طبيبك أنك تتناول هذا الدواء إذا:</strong><br />- كنت على وشك البدء في تناول أي دواء جديد</p><p>- كنتي حامل أو تخططين للحمل. أخبري طبيبك على الفور، ومع ذلك لا توقفي تناول الدواء قبل التحدث مع طبيبك. عند التناول أثناء الحمل، فإن الأدوية المشابهة (مثبطات استرجاع السيرونين الانتقائية) قد تسبب زيادة خطر حدوث حالة خطيرة عند الأطفال يطلق عليها فرط التوتر الرئوي المستمر لدى حديثي الولادة (PPHN)، مما يجعل الطفل الوليد يتنفس بشكل أسرع ويبدو مائلاً للزرقة. تبدأ هذه الأعراض عادة خلال أول 24 ساعة بعد ولادة الطفل. إذا حدث ذلك لطفلك ينبغي عليك الاتصال بالقابلة و/أو الطبيب على الفور.</p><p>- كنتي ترضعين رضاعة طبيعية أو تخططين للإرضاع الطبيعي. من غير المعروف ما إذا كان ميرتازابين يمر إلى لبن الثدي. سوف يناقش طبيبك معك مخاطر وفوائد تناول هذا الدواء أثناء الرضاعة الطبيعية.</p><p>- كنت على وشك إجراء أي اختبارات بالدم</p><p>- كنت ستخضع لجراحة أو تخدير أو سيتم احتجازك في المستشفى. يمكن لطبيبك بين حين وآخر للتأكد من أن الدواء يعمل أو للوقاية من الآثار الجانبية. اذهب للطبيب بشكل دوري لإجراء فحص. أخبر طبيبك على الفور إذا أصبت بحمى أو رعشة أو احتقان الحلق أو قرح الفم أو علامات أخرى للعدوى.</p><p>في حالات نادرة، قد يسبب ميرتازابين نقصًا في خلايا الدم البيضاء، مما يؤدي إلى نقص مقاومة الجسم للعدوى. &nbsp;قد تظهر هذه الأعراض بعد 2-6 أسابيع من العلاج.</p><p>- أخبر طبيبك على الفور أو اذهب لأقرب مستشفى لطلب العلاج إذا راودتك أي أفكار انتحارية أو أي تغيرات عقلية/مزاجية أخرى. الشباب الذين تتراوح أعمارهم بين 18-24 عامًا معرضون بشكل أكبر لهذه الأعراض.</p><p>في بعض الأحيان، فإن أعراض الاكتئاب أو الحالات النفسية الأخرى قد تتضمن أفكارًا بإيذاء الذات أو الانتحار. &nbsp;حتى يظهر التأثير المضاد للاكتئاب للدواء بشكل كامل، قد تزيد هذه الأعراض في الأسابيع القليلة الأولى من العلاج.</p><p>- إذا لاحظت أنت أو شخص آخر تعرفه أيًا من هذه العلامات التحذيرية من الانتحار أثناء تناول هذا الدواء، &nbsp;اتصل بطبيبك أو المهني الصحي على الفور أو اتجه لأقرب مستشفى لتلقي العلاج:</p><p style="margin-right:40px">&bull; أفكار أو حديث عن الموت أو الانتحار<br />&bull; أفكار او حديث عن إيذاء الذات أو إيذاء الآخرين<br />&bull; أي محاولات حديثة لإيذاء الذات<br />&bull; زيادة السلوك العدواني أو حدة المزاج أو الهياج.<br />&bull; أي ذكر للانتحار أو العنف يجب أن يؤخذ بجدية.</p><p>- إذا كنت مصابًا بمرض السكري، قم بمتابعة مستويات السكر في الدم لديك. قد يتطلب الأمر ضبط جرعة دواء السكري الخاص بك.<br />- أخبر طبيبك إذا لم تتناول دواءك تمامًا كما تم وصفه لك، لأي سبب من الأسباب. وإلا فقد يعتقد طبيبك أن الدواء غير فعال ويغير العلاج الخاص بك مع عدم وجود داعي لذلك. أخبر طبيبك إذا كنت تشعر أن هذا الدواء غير مفيد لك في حالتك. أخبر أي أطباء أو أطباء أسنان أو صيادلة آخرين يعالجونك بأنك تتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>أخبر طبيبك أو الصيدلي بمجرد أن تشعر بأنك لست على ما يرام أثناء تناول ميرتازابين أو إذا كانت لديك أي استفسارات أو مخاوف. لا تنزعج من الآثار الجانبية التالية. قد لا تعاني من أي منها. جميع الأدوية يمكن أن يكون لها آثار جانبية. في بعض الأحيان تكون هذه الآثار الجانبية خطيرة ولكن في معظم الاحيان لا تكون كذلك.</p><p>أخبر طبيبك أو الصيدلي إذا لاحظت أيًا من الآثار الجانبية التالية وكنت تشعر بالقلق منها. تتضمن هذه القائمة الآثار الجانبية الأكثر شيوعًا. هذه الآثار الجانبية تكون خفيفة في معظم الأحيان:</p><p>&bull; النعاس&nbsp;<br />&bull; الصداع<br />&bull; التعب، الشعور بالضعف<br />&bull; زيادة الشهية، زيادة الوزن&nbsp;<br />&bull; جفاف الفم<br />&bull; الإسهال<br />&bull; الدوار أو الضعف العَرَضي، وخاصة عند الاستيقاظ بشكل سريع من وضع الاستلقاء أو الجلوس&nbsp;<br />&bull; تورم الكاحل أو القدم نتيجة لتراكم السوائل (الودمة)&nbsp;<br />&bull; احتباس السوائل مع زيادة الوزن<br />&bull; طفح خفيف&nbsp;<br />&bull; كوابيس/أحلام جلّية&nbsp;<br />&bull; وخز في أصابع اليدين أو القدمين<br />&bull; ألم في المفاصل<br />&bull; ألم في العضلات&nbsp;<br />&bull; تململ الساقين&nbsp;</p><p>&nbsp;</p><p><strong>أخبر طبيبك في أقرب وقت ممكن إذا لاحظت أيًا مما يلي. هذه الآثار الجانبية يمكن أن تكون خطيرة. قد تحتاج للرعاية الطبية. معظم هذه الآثار الجانبية نادرة.</strong></p><p>&bull; الحكة أو أي نوع من الطفح الجلدي أو البثور، تقشر أو تساقط الجلد<br />&bull; انخفاض مستويات الصوديوم (الشعور بالتعب، التشوش، الإنهاك، مع ضعف أو تشنجات في العضلات)<br />&bull; الشعور بالهياج أو القلق أو الانفعال&nbsp;<br />&bull; الشعور بالجزع الشديد والحاجة الطاغية للتحرك<br />&bull; عدم القدرة على المشي بشكل سليم<br />&bull; خدر في الفم<br />&bull; عدم القدرة على النوم أو البقاء نائمًا (*)<br />&bull; التغيرات غير المعتادة في السلوك<br />&bull; الارتجاج أو الارتعاش<br />&bull; احتباس عام للسوائل مع زيادة الوزن<br />&bull; حمى، التهاب الحلق، قرح الفم، اضطرابات في الجهاز المعدي المعوي (المعدة، الأمعاء)<br />&bull; ألم في العين (علامة محتملة على الجلوكوما أو ارتفاع الضغط داخل العين)<br />* قد تكون هناك أعراض للاكتئاب.</p><p><strong>إذا شعرت بأي مما يلي، أوقف تناول الدواء واتصل بطبيبك على الفور أو توجه إلى قسم الحوادث والطوارئ في أقرب مستشفى. هناك آثار جانبية خطيرة جدًا وعادة ما تكون نادرة جدًا. قد تحتاج للرعاية الطبية العاجلة أو الاحتجاز بالمستشفى.</strong></p><p>&bull; أفكار أو أفعال تتعلق بالانتحار أو إيذاء الذات<br />&bull; تفاعل خطير بالجلد يبدأ بمناطق حمراء مؤلمة ثم بثور كبيرة، وينتهي بتقشير طبقات من الجلد. يمكن أن يكون ذلك مصحوبًا بحمى ورعشة وألم في العضلات، والشعور العام باعتلال الصحة.<br />&bull; ألم في الصدر، سرعة أو عدم انتظام ضربات القلب.<br />&bull; الصرع أو النوبات (نوبات صرعية)<br />&bull; الارتجاج أو الارتعاش<br />&bull; تقلصات مفاجئة في العضلات<br />&bull; إغماء، كحة ومشاكل في التنفس (علامات الجلطة الدموية على الرئة)<br />&bull; نوبة استثارة مفرطة (الهوس)<br />&bull; التشوش<br />&bull; الهلاوس (سمعية، بصرية أو الشعور بأشياء غير موجودة)<br />&bull; اصفرار لون العينين، ويرجح أن يكون ذلك بسبب وجود مشاكل في الكبد<br />&bull; حمى، تعرق، زيادة معدل ضربات القلب، إسهال غير متحكم فيه، تقلصات في العضلات، ارتجاف، انعكاسات مفرطة، تململ واضطراب، تغيرات مزاجية وفقد الوعي (متلازمة السيروتونين).</p><p>قد تحدث آثار جانبية أخرى غير مدرجة في هذه النشرة لدى بعض الأشخاص. قد تحدث بعض الآثار الجانبية دون وجود أعراض، ويمكن اكتشافها عن طريق الاختبارات. على سبيل المثال، ارتفاع ضغط الدم، ارتفاع الكوليسترول أو مستويات الدهون، تغيرات في مستويات خلايا الدم البيضاء أو الحمراء.</p><p>&nbsp;</p><p><strong>تفاعلات الحساسية</strong><br />إذا كنت تعتقد أنك تعاني من تفاعل حساسية لميرتازابين، لا تتناول أي جرعة أخرى من هذا الدواء واتصل بطبيبك على الفور أو توجه إلى قسم الحوادث والطوارئ في أقرب مستشفى.<br />أعراض تفاعل الحساسية قد تتضمن بعض أو كل ما يلي:</p><p>&bull; الكحة، ضيق التنفس، الصفير أو صعوبة التنفس<br />&bull; تورم الوجه أو الشفتين أو اللسان أو الحلق أو أجزاء أخرى من الجسم<br />&bull; الطفح أو الحكة أو الشرى على الجلد<br />&bull; الإغماء<br />&bull; أعراض شبيهة بحمى الكلأ.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ هذا الدواء بعيدًا عن متناول الأطفال.<br />- خزانة مغلقة يبلغ ارتفاعها متر ونصف المتر فوق سطح الارض هي مكان جيد لتخزين الأدوية.</p><p>- احفظ الدواء في عبوته الأصلية حتى موعد تناوله.<br />- إذا أخرجت الدواء من عبوته الأصلية، فقد يفقد مفعوله.<br />- احفظ الدواء في مكان بارد وجاف في درجة حرارة أقل من 30 درجة مئوية.<br />- لا تخزن هذا الدواء، أو أي دواء آخر ،في الحمام أو بالقرب من الحوض. لا تترك الدواء على حافة النافذة أو في السيارة. يمكن للحرارة والرطوبة إتلاف بعض الأدوية.<br />- التخلص من الدواء: إذا طلب منك طبيبك أو الصيدلي وقف تناول هذا الدواء أو إذا انتهى تاريخ الصلاحية له، يمكن للصيدلي أن يتخلص من الدواء المتبقي بشكل آمن.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي ميرتازابين.<br />&bull; باقي المواد هي لاكتوز ،سيليكا غروانية لا مائية ،كروس كاميلوز الصوديوم، ستيرات الماغنسيوم، هيبروميلوز، هيدروكي بروبيل سليلوز، ماكروجيل 8000، ثاني أكسيد التيتانيوم، أكسيد الحديد الأحمر<br />&nbsp; CI 77491 (30 ملجم فقط) و أكسيد الحديد الأصفر CI 77492 (15 ملجم و30 ملجم فقط).</p><p>هذا الدواء خالي من الجلوتين والسكروز والتارتازين والأصباغ الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>أقراص 15 ملجم</strong><br />أقراص مغلفة بطبقة رقيقة ذات لون أصفر باهت، بيضاوية الشكل، محزَّزة، مطبوع على أحد الجانبين &quot;APO&quot; و&quot;MI&quot; &quot;15&quot; على الجانب الآخر.<br />متوفر في شرائط تحتوي على 30 قرصًا (3 شرائط بكل شريط 10 أقراص).</p><p><strong>أقراص 30 ملجم</strong><br />أقراص مغلفة بطبقة رقيقة ذات لون وردي باهت، بيضاوية الشكل، محزَّزة، مطبوع على أحد الجانبين &quot;APO&quot; و&quot;MI&quot; &quot;30&quot; &nbsp;على الجانب الآخر.<br />متوفر في شرائط تحتوي على 30 قرصًا (3 شرائط بكل شريط 10 أقراص).</p><p><strong>أقراص 45 ملجم</strong><br />أقراص مغلفة بطبقة رقيقة ذات لون أبيض مطفأ، بيضاوية الشكل، غير محزَّزة، مطبوع على أحد الجانبين &quot;APO&quot; و&quot;MI-45&quot; على الجانب الآخر.<br />متوفر في شرائط تحتوي على 30 قرصًا (3 شرائط بكل شريط 10 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق</strong><br />شركة أبوتكس إنك<br />150 سيجنت درايف<br />تورنتو، أونتاريو M9L 1T9<br />ت: 18002684623، ف: 18006099444<br />www.apotex.com</p><p><strong>المصنع</strong><br />شركة أبوتكس إنك<br />50 شارع ستاينواي&nbsp;<br />إتوبيكوك، أونتاريو&nbsp;<br />كندا M9W 6Y3</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 06/2018

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MIRTAZA
Mirtazapine Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MIRTAZA Tablets are supplied as:

MIRTAZA (mirtazapine) 15 mg Tablets: Pale yellow, oval shaped, scored, film coated tablets, imprinted “APO” on one side and “MI” bisect “15” on the other side.  Available in bottles and blister pack of 30 tablets.

MIRTAZA (mirtazapine) 30 mg Tablets: Light pink, oval shaped, scored, film coated tablets, imprinted “APO” on one side and “MI” bisect “30” on the other side. Available in bottles and blister pack of 30 tablets.

MIRTAZA (mirtazapine) 45 mg Tablets: White to off-white, oval shaped, unscored, film coated tablets, imprinted “APO” on one side and “MI-45” on the other side.  Available in bottles and blister pack of 30 tablets.

Composition: Each film-coated tablet contains 15 mg, 30 mg or 45 mg of mirtazapine. each tablet also contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, titanium dioxide, red iron oxide (30 mg tablets) and yellow iron oxide (15 mg and 30 mg tablets).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MIRTAZA is available in dosage strengths of 15 mg, 30 mg & 45 mg per tablet.

* Not all packs available.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depression.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirtazapine should be taken orally, if necessary with fluid, and swallowed without chewing.</p><p>&nbsp;</p><p><strong>Adults</strong><strong> </strong><strong>&ndash; </strong>Treatment should begin with 15 mg daily. The dosage generally needs to be increased to obtain an optimal clinical response. The effective daily dose is usually between 30 and 45 mg but responses have been observed at 60 mg per day.</p><p>&nbsp;</p><p><strong>Elderly</strong><strong> </strong><strong>&ndash; </strong>The recommended dose is the same as that for adults. In elderly patients an increase in dosing should be done under close supervision to elicit a satisfactory and safe response.</p><p>&nbsp;</p><p>The clearance of mirtazapine may be decreased in patients with renal or hepatic insufficiency. This should be taken into account when prescribing mirtazapine to this category of patients (see WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p><p>Mirtazapine has a half-life of 20&ndash;40 hours and, therefore, mirtazapine is suitable for once-a-day administration. I t should be taken preferably as a s ingle night-time dose before going to bed. Mirtazapine may also be given in sub-doses equally divided over the day (once in the morning and once at night-time).</p><p>&nbsp;</p><p>Treatment should preferably be continued until the patient has been completely symptom-free for 4&ndash;6 months. After this, treatment can be gradually discontinued. Mirtazapine generally begins to exert its effect after 1&ndash;2 weeks of treatment.</p><p>&nbsp;</p><p>Treatment with an adequate dose should result in a positive response within 2-4 weeks. With an insufficient response, the dose can be increased up to the maximum dose. If there is no response within a further 2&ndash;4 weeks, then treatment should be stopped.</p><p>&nbsp;</p><p><strong>Children and Adolescents (&lt; 18 years of age)</strong></p><p>In placebo-controlled trials, safety and efficacy of mirtazapine in the treatment of children and adolescents under the age of 18 years with major depressive disorder have not been established. Safety and efficacy in this population cannot be extrapolated from adult data. Th erefore, mirtazapine should not be used in children and adolescents under the age of 18 years.</p><p>Mirtazapine should be taken orally, if necessary with fluid, and swallowed without chewing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to mirtazapine or to any of the excipients.

- Monoamine oxidase inhibitors (MAOls) as concomitant therapy.  It is recommended that mirtazapine not be used in combination with MAOls or within 14 days of initiating or discontinuing therapy with an MAOI (see INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical Worsening and Suicide Risk</strong></p><p>The risk of suicidality (suicidal ideation and suicidal behaviours) is inherent in depression and may persist until significant remission occurs. &nbsp;The risk must be considered in all depressed patients. &nbsp;Patients with depression may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and/or behaviours whether or not they are taking antidepressant medication, and this risk may persist until significant remission occurs. &nbsp;Suicide is a known risk in depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.</p><p>&nbsp;</p><p>As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored for clinical worsening and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt in onset, or was not part of the patient&#39;s presenting symptoms. &nbsp;Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition and/or the emergence of suicidal ideation or behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. &nbsp;Patients with co- morbid depression associated with other psychiatric disorders being treated with antidepressants should be similarly observed for clinical worsening and suicidality.</p><p>&nbsp;</p><p>Pooled analysis of short-term placebo-controlled trials of antidepressants drugs [selective serotonin reuptake inhibitors (SSRls) and others] showed that these drugs increased the risk of suicidal and/or behaviours in children, adolescents and young adults (aged 18&ndash;24 years) with major depressive disorders (MDD) and other psychiatric disorders during the initial treatment (generally the first one to two months). Short-term studies did not show an increase in the risk of suicidality with antidepressants, compared to placebo, in adults aged 65 years and older.</p><p>&nbsp;</p><p>The pooled analysis of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD) or other psychiatric disorders included a total of 24 short- term trials (4 to 16 weeks) of 9 antidepressant drugs in over 4,400 patients.&nbsp; The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. &nbsp;There was considerable variation in the risk of suicidality among drugs, but a tendency towards an increase in the younger patients for almost all drugs studied. &nbsp;There were differences in absolute risk of suicidality across different indications, with the highest incidence in MDD trials. &nbsp;The risk differences (drug vs. &nbsp;placebo) however, were relatively stable within age strata and across indications.</p><p>&nbsp;</p><p>No suicides occurred in any of the paediatric trials. &nbsp;There were few suicides in the adult trials, but the number was not sufficient to reach any conclusion about the effect of antidepressants on suicide. &nbsp;It is unknown whether suicidality risk extends to longer-term use, i.e. beyond several months. &nbsp;However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.</p><p>&nbsp;</p><p>Symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania and mania have been reported in adults, adolescents and children being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric. &nbsp;Although a causal link between the emergence of such symptoms and either worsening of depression and/or emergence of suicidality has not been established, there is concern that such symptoms may be precursors of emerging suicidality.</p><p>&nbsp;</p><p>Families and caregivers of children and adolescents being treated with antidepressants for major depressive disorder or for any other condition (psychiatric or non-psychiatric) should be informed about the need to monitor these patients for the emergence of agitation, irritability, unusual changes in behaviour and other symptoms described above, as well as the emergence of suicidality and to report such symptoms immediately to healthcare providers. &nbsp;It is particularly important that monitoring be undertaken during the initial few months of antidepressants treatment or at times of dose increase or decrease.</p><p>&nbsp;</p><p>Prescriptions for mirtazapine should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.</p><p>&nbsp;</p><p><strong>Conditions which need supervision</strong></p><p>Careful dosing as well as regular and close monitoring is necessary in patients with:</p><ul><li><strong>Epilepsy and organic brain syndrome </strong>(see UNDESIRABLE EFFECTS). Mirtazapine should be introduced cautiously in patients who have had a history of seizures. Treatment should be discontinued in any patient who develops seizures, or where there is an increase in seizure frequency.</li><li><strong>Hepatic impairment.</strong></li><li><strong>Renal insufficiency</strong>. &nbsp;Mirtazapine is substantially excreted by the kidney (75%) and the risk of decreased clearance of this drug is greater in patients with impaired renal function.</li><li><strong>Cardiac diseases. </strong>Such as conduction disturbances, angina pectoris and recent myocardial infarct, where normal precautions should be taken and concomitant medicines carefully administered.</li><li><strong>Low blood pressure </strong>and conditions that would predispose patients to hypotension (dehydration, hypovolaemia and treatment with antihypertensive medication).</li><li><strong>Diabetes Mellitus</strong>. In patients with diabetes, antidepressants may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted and close monitoring is recommended.</li></ul><p>&nbsp;</p><p><strong>Like with other antidepressants, the following should be taken into account:</strong></p><ul><li>Care should be taken in patients with micturition disturbances like prostate hypertrophy (although problems are not to be expected because mirtazapine possesses only very weak anticholinergic activity).</li><li>Acute narrow-angle glaucoma and increased intra-ocular pressure (however mirtazapine has weak anticholinergic activity)</li><li>Worsening of psychotic symptoms can occur when antidepressants are administered to patients with schizophrenia or other psychotic disturbances; paranoid thoughts can be intensified.</li><li>A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed that treating such an episode with an antidepressant alone can increase the likelihood of precipitation of a mixed/manic episode in patients at risk of bipolar disorder. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder and depression. When the depressive phase of the bipolar disorder is being treated, it can transform into the manic phase. Patients with a history of mania/hypomania should be closely monitored. Mirtazapine should be discontinued in any patient entering a manic phase.</li><li>Akathisia/psychomotor restlessness: The use of antidepressants has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</li><li>Mirtazapine is not addictive. &nbsp;Post-marketing experience shows that abrupt termination of treatment after long term administration may sometimes result in withdrawal symptoms. The majority of withdrawal reactions are mild and self limiting. &nbsp;Among the various reported withdrawal symptoms, dizziness, agitation, anxiety, headache and nausea are the most frequently reported. Even though they have been reported as withdrawal symptoms, it should be realized that these symptoms may be related to underlying disease. &nbsp;As advised in DOSAGE AND ADMINISTRATION, it is recommended to discontinue treatment with mirtazapine gradually.</li></ul><p>&nbsp;</p><p><strong>Jaundice</strong></p><p>Treatment should be discontinued if jaundice occurs.</p><p>&nbsp;</p><p><strong>Hyponatraemia</strong></p><p>Hyponatraemia has been reported very rarely with the use of mirtazapine. Caution should be exercised in patients at risk, such as elderly patients or patients concomitantly treated with medications known to cause hyponatraemia.</p><p>&nbsp;</p><p><strong>Serotonin syndrome</strong></p><p>Development of serotonin syndrome may occur in association with treatment with SSRIs and SNRIs, particularly when given in combination with MAO-Is or other serotonergic agents (see INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF</p><p>INTERACTION). Symptoms and signs of serotonin syndrome include rapid onset of neuromuscular excitation (hyperreflexia, incoordination, myoclonus, tremor), altered mental status (confusion, agitation, hypomania) and autonomic dysfunction (diaphoresis, diarrhoea, fever, shivering and rapidly fluctuating vital signs). Treatment with mirtazapine should be discontinued if such events occur and supportive symptomatic treatment initiated. From post marketing experience it appears that serotonin syndrome occurs very rarely in patients treated with mirtazapine alone (see UNDESIRABLE EFFECTS).</p><p>&nbsp;</p><p><strong>Sucrose</strong></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p><strong>Elderly Patients</strong></p><p>Elderly patients are often more sensitive, especially with regard to the undesirable effects of antidepressants. &nbsp;During clinical research with mirtazapine, undesirable effects have not been reported more often in elderly patients than in other age groups. (Refer to CLINICAL TRIALS and DOSAGE and ADMINISTRATION).</p><p>&nbsp;</p><p><strong>Use in Children and Adolescents (&lt; 18 years)</strong></p><p>Mirtazapine should not be used to treat children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviours and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p>&nbsp;</p><p><strong>Neutropenia, Agranulocytosis</strong></p><p>Bone marrow depression, usually presenting as granulocytopenia or agranulocytosis, has been reported during treatment with mirtazapine. The symptoms mostly appear after 2&ndash;6 weeks of treatment. The bone marrow depression is, in general, reversible after termination of treatment.</p><p>&nbsp;</p><p>However in very rare cases agranulocytosis can be fatal. &nbsp;Reversible agranulocytosis has been reported as a rare occurrence in clinical studies with mirtazapine. In the post-marketing period with mirtazapine, very rare cases of agranulocytosis have been reported, mostly reversible, but in some cases fatal. &nbsp;All fatal cases concerned patients over 65 years. &nbsp;Post-marketing data indicate that the rate of occurrence of agranulocytosis and agranulocytosis-like disorders (whether or not causally related) amongst mirtazapine users is no greater than that in the background population.</p><p>&nbsp;</p><p>One should, therefore, be alert for symptoms like fever, sore throat, stomatitis or other signs of infections.&nbsp; If such symptoms occur the treatment should be stopped and blood counts taken.</p><p>&nbsp;</p><p><strong>Carcinogenicity</strong></p><p>An 18-month carcinogenicity study in mice showed an increase in the development of hepatic tumours in males after mirtazapine treatment at oral doses of 20 mg/kg/day and above. &nbsp;In a two year carcinogenicity study in rats, oral doses of mirtazapine greater than 20 mg/kg/day were associated in males with an increased incidence of thyroid follicular cell adenomas and carcinomas.</p><p>&nbsp;</p><p>Since the only tumours found in carcinogenicity studies with mice and rats were considered to be species-specific, non-genotoxic responses associated with long-term treatment with hepatic enzyme inducers, mirtazapine is not expected to possess carcinogenic potential at therapeutic dosages in the clinic.</p><p>&nbsp;</p><p><strong>Genotoxicity</strong></p><p>Mirtazapine was not genotoxic in a series of tests for gene mutation and chromosomal and DNA damage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pharmacokinetic Interactions</u></strong></p><ul><li>Mirtazapine is extensively metabolised by CYP2D6 (resulting in the 8-hydroxy metabolite) and CYP3A4 (N-demethyl and N-oxide metabolites) and to a lesser extent by CYP1A2. &nbsp;An interaction study with healthy volunteers showed no influence of paroxetine, a CYP2D6 inhibitor, on mirtazapine pharmacokinetics in steady state.</li><li>Co-administration of the potent inhibitor CYP3A4, ketoconazole, in healthy male volunteers increased mirtazapine peak plasma concentration levels and AUC by approximately 40% and 50% respectively</li><li>When cimetidine (weak inhibitor of CYP1A2, CYP2D6 and CYP3A4) is administered with mirtazapine, the mean plasma concentration of mirtazapine may increase more than 50%. &nbsp;The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started or increased when cimetidine treatment is ended. Caution should be exercised and the dose may have to be decreased when co-administering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, ketoconazole, erythromycin, cimetidine or nefazodone.</li><li>Carbamazepine and phenytoin, inducers of CYP3A4, increased mirtazapine clearance about two-fold, resulting in a decrease in plasma levels of 45&ndash;60%. When carbamazepine, phenytoin or another inducer of drug metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased. &nbsp;If treatment with an inducer is stopped, the mirtazapine dose may have to be decreased.</li><li>In <em>in vivo </em>interaction studies, mirtazapine did not influence the pharmacokinetics of paroxetine (CYP2D6 substrates), carbamazepine or phenytoin (CYP3A4 inducers), amitriptyline or cimetidine.</li><li>In a mirtazapine and lithium interaction study, the steady state pharmacokinetics of lithium were not affected by co-administration of a single oral dose of 30 mg mirtazapine. &nbsp;Correspondingly, the single dose pharmacokinetics of mirtazapine were not affected by the lithium steady state.</li></ul><p>&nbsp;</p><p><strong><u>Pharmacodynamic Interactions</u></strong></p><ul><li>Mirtazapine should not be administered concomitantly with MAO lnhibitors or within two weeks after discontinuation of MAO Inhibitor therapy. In the opposite way about two weeks should pass before patients treated with mirtazapine should be treated with MAO inhibitors. (see CONTRAINDICATIONS). In addition, as with SSRIs, co-administration with other serotonergic active substances (L-tryptophan, triptans, tramadol, linezolid, SSRIs, venlafaxine, lithium and St John&rsquo;s Wort- hypericum perforatum- preparations) may lead to an incidence of serotonin associated effects. (see WARNINGS AND PRECAUTIONS). Caution should be advised and a closer clinical monitoring is required when these active substances are combined with mirtazapine.</li><li>Mirtazapine may potentiate the sedative effects of benzodiazepines and other sedatives (especially antipsychotics, antihistamine H1 antagonists, opioids). Caution should be taken when these drugs are prescribed together with mirtazapine.</li><li>Mirtazapine may potentiate the central nervous dampening action of alcohol; patients using mirtazapine should therefore be advised to avoid alcohol during tasks which require concentration and alertness.</li><li>Mirtazapine dosed at 30 mg daily caused a small but statistically significant increase of the INR in subjects treated with warfarin. Both at continuing stable doses and higher doses of mirtazapine, a more pronounced effect cannot be excluded. &nbsp;It is advisable to monitor the prothrombin time more carefully in case of concomitant treatment of warfarin with mirtazapine.</li></ul><p>From post-marketing experience it appears that serotonin syndrome occurs very rarely in patients treated with mirtazapine in comb<em>ination with SSRIs or v</em>enlafaxine. &nbsp;If the combination is considered therapeutically necessary, dosage changes should be made with caution and there should be adequate close monitoring for early signs of serotonergic overstimulation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects on Fertility</strong></p><p>In a fertility study in rats, mirtazapine was given at doses up to 100 mg/kg (ca. 20 times the recommended human dose of 45 mg on a mg/m2 basis).&nbsp; The drug did not affect mating and conception, but oestrus cycling was disrupted at doses that were 3 or more times the recommended human dose of 45 mg on a mg/m2 basis.</p><p>&nbsp;</p><p><strong>Use in Pregnancy (Category C)</strong></p><p><em>Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.</em></p><p><em>&nbsp;</em></p><p>There are insufficient clinical data to assess the possible effect of mirtazapine on pregnancy. Oral dosing of pregnant rats with mirtazapine at 100 mg/kg/day was associated with a reduction in survival of the offspring, and an increased incidence of postnatal mortality. &nbsp;Mirtazapine was not teratogenic in rats at these dose levels or in rabbits at oral doses up to 40 mg/kg/day.</p><p>&nbsp;</p><p>Although studies in animals have not shown any teratogenic effects of toxicological significance the safety of mirtazapine in human pregnancy has not been established. Epidemiological data have suggested that the use of SSRIS in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN to mirtazapine treatment, this potential risk cannot be ruled out, taking into account the related mechanism of action (increase in serotonin concentrations).</p><p>&nbsp;</p><p>Mirtazapine should be used during pregnancy only if it is clearly needed. Women of child- bearing potential should employ an adequate method of contraception if taking mirtazapine.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>Although animal experiments show that mirtazapine is excreted only in very small amounts in the milk, post-natal mortality was increased when lactating rats were given mirtazapine orally at 100 mg/kg/day.</p><p>&nbsp;</p><p>The use of mirtazapine in breast-feeding mothers is not recommended since no human data in breast milk are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirtazapine may impair concentration and alertness (more commonly in the initial phase of treatment). &nbsp;Patients treated with mirtazapine should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the treatment does not affect them adversely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical Trials</strong></p><p>Depressed patients display a number of symptoms that are associated with the illness itself. &nbsp;It is, therefore, sometimes difficult to ascertain which symptoms are a result of the illness itself and which are a result of treatment with mirtazapine.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>SYSTEM ORGAN</strong><strong> </strong><strong>CLASS</strong></p></td><td style="vertical-align:top"><p><strong>COMMON</strong></p><p><strong>(&gt; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>UNCOMMON</strong></p><p><strong>(&gt; 1/1000 to &le; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>RARE</strong></p><p><strong>(&gt; 1/10,000 to &le; 1/1000)</strong></p></td></tr><tr><td style="vertical-align:top"><strong>Blood &amp; Lymphatic System Disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Granulocytopaenia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism &amp; Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mania</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nightmares/vivid dreams (paroniria)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous&nbsp;</strong><strong>System</strong></p><p><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drowsiness/ sedation generally occurring during the first weeks</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epileptic seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions (insults)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myoclonus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paraesthesia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restless legs (hyperkinesia)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Orthostatic hypotension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevations in serum transaminase activities</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin&nbsp;</strong><strong>&amp; Subcutaneous<strong> </strong>Tissue</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exanthema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>Connective&nbsp;</strong><strong>Tissue &amp; Bone Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myalgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>Disorders</strong><strong> </strong><strong>&amp;</strong></p><p><strong>Administration</strong><strong> &nbsp;Site Conditions</strong></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generalized or local oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Post-Marketing Reports</strong></p><p><u>Skin and Subcutaneous Tissue Disorders</u></p><p>Steven-Johnson syndrome, dermatitis bullous, erythema multiforme, toxic epidermal necrolysis, rash (including erythematous and maculopapular).</p><p>Rare cases of increased sweating, alopecia, pruritus and urticaria.</p><p>&nbsp;</p><p><u>Musculoskeletal Connective Tissue and Bone Disorders</u></p><p>Arthralgia, myalgia.</p><p>&nbsp;</p><p><u>Nervous System Disorders</u></p><p>Serotonin syndrome, somnolence (i.e. drowsiness sedation), impaired concentration, dizziness, paraesthesia, headache, hyperkinesia.</p><p>Rare cases of cerebrovascular disorder, convulsions, tremor and myoclonus, movement disorders**. Very rare cases of oral paraesthesia.</p><p>&nbsp;</p><p><u>Psychiatric Disorders</u></p><p>Suicidal ideation***, suicidal behaviour***, confusion, agitation, aggression, paroniria.</p><p>Less common or rare occurrences of nightmares/vivid dreams, hallucination, mania, depression, anxiety*, insomnia*, and psychomotor restlessness**.</p><p>&nbsp;</p><p><u>Gastrointestinal Disorders</u></p><p>Nausea, diarrhoea, dry mouth.</p><p>Less common or rare cases of stomatitis.</p><p>Very rare cases of oral hypoaesthesia and mouth oedema.</p><p>&nbsp;</p><p><u>Hepatobiliary Disorders</u></p><p>Hepatic function abnormal, elevated hepatic enzymes or transaminases. Rare cases of jaundice, hepatitis.</p><p>&nbsp;</p><p><u>Metabolism and Nutritional Disorders</u></p><p>Hyponatraemia, increased appetite, rare cases of hypercholesterolaemia, hyperlipidaemia.</p><p>&nbsp;</p><p><u>Cardiac Disorders</u></p><p>Tachycardia, palpitations.</p><p>Rare cases of arrhythmia, myocardial infarction, chest pain.</p><p>&nbsp;</p><p><u>Vascular Disorders</u></p><p>Dependent oedema, hypertension, orthostatic hypotension. Rare cases of thromboembolic disorder, pulmonary embolism.</p><p>&nbsp;</p><p><u>Blood and Lymphatic System Disorders</u></p><p>Leukopenia, granulocytopoenia.</p><p>Rare cases of agranulocytosis, (see WARNINGS AND PRECAUTIONS), rare cases of thrombocytopenia, pancytopenia, anaemia, aplastic anaemia, eosinophilia and coagulation disorder.</p><p>&nbsp;</p><p><u>Renal and Urinary Disorders</u></p><p>Rare cases of urinary retention.</p><p>&nbsp;</p><p><u>General Disorders and Administration Site Conditions</u></p><p>Oedema including generalised, peripheral and face oedema, fatigue/asthenia. Rare cases of pyrexia, syncope, chest pain and drug withdrawal symptoms.</p><p>&nbsp;</p><p><u>Investigation</u></p><p>Weight gain.</p><p>&nbsp;</p><p><u>Eye Disorders</u></p><p>Very rare cases of glaucoma.</p><p>&nbsp;</p><p>*: upon treatment with antidepressants in general, anxiety and insomnia (which may be symptoms of depression) can develop or become aggravated. Under mirtazapine treatment, development or aggravation of anxiety and insomnia has been reported very rarely.</p><p>**:&nbsp; including akathisia, hyperkinesia.</p><p>***: cases of suicidal ideation and suicidal behaviours have been reported during mirtazapine therapy or early after treatment discontinuation (see WARNINGS AND PRECAUTIONS)</p><p>&nbsp;</p><p>-&nbsp; To report any side effect(s)</p><p><strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Toll-free: 8002490000</p><p>&middot;&nbsp; &nbsp; &nbsp;E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>Other GCC States:</strong></p><table style="width:500px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>Post-marketing experience concerning overdose with mirtazapine alone indicates that symptoms are usually mild. The symptoms of overdose are an exaggeration of the pharmacological actions of mirtazapine and may include symptoms such as dizziness, impaired consciousness (confusion, disorientation, stupor, coma), agitation, tremor and tachycardia, hypertension and hypotension.</p><p>As with all overdose attempts, the possibility of multiple drug ingestion should be borne in mind.</p><p>As with other antidepressants in general, serious outcomes, including fatalities, are possible at dosages much higher that the therapeutic dose, especially with mixed overdoses.</p><p>&nbsp;</p><p><strong>Treatment</strong></p><p>Cases of overdose should receive appropriate symptomatic and supportive therapy for vital functions.</p><p>&nbsp;</p><p><strong>For information on the management of overdose, contact the Poison Information Centre.</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirtazapine is an antagonist of central &alpha;2-auto and hetero-adrenoceptors which causes an increase in both noradrenaline and serotonin release. &nbsp;The effect of released serotonin is exerted specifically via 5-HT1 type receptors, because 5-HT2 and 5-HT3 type receptors are specifically blocked by mirtazapine.</p><p>&nbsp;</p><p>Both the enantiomers of mirtazapine are presumed to contribute to the antidepressant activity, the S(+) enantiomer by blocking &alpha;2-auto and hetero-adrenoceptors and 5-HT2 receptors and the R(-) enantiomer by blocking &alpha;2 hetero-adrenoceptors and 5-HT3 receptors.&nbsp; In one study, there was no efficacy difference indicated between the two enantiomers, despite their different receptors affinities.</p><p>&nbsp;</p><p>The histamine H1-antagonistic activity of mirtazapine is responsible for its sedative properties. Mirtazapine is generally well tolerated. &nbsp;It has practically no anticholinergic activity.</p><p>Mirtazapine has been associated with acute postural hypotension in healthy volunteer studies but less so in patient studies (see UNDESIRABLE EFFECTS).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration of mirtazapine tablets, the active substance mirtazapine is rapidly and well absorbed (bioavailability ~ 50%), reaching peak plasma levels after about 2 hours. Food intake has no clinically significant influence on the pharmacokinetics of mirtazapine.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Binding of mirtazapine to plasma proteins is approx.&nbsp; 85%. The half-life of elimination ranged from 20&ndash;40 hours; longer half-lives, up to 65 hours, have occasionally been recorded and shorter half-lives have been seen in young men. &nbsp;The half-life of elimination is sufficient to justify once- a-day dosing. &nbsp;Steady state is reached after 3&ndash;6 days, after which there is no further accumulation. &nbsp;Mirtazapine displays linear pharmacokinetics within the recommended dose range.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p><em>In vitro </em>data from human liver microsomes indicate that cytochrome P450 enzymes CYP2D6 and CYP1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas CYP3A4 is considered to be responsible for the formation of the N-demethyl and N-oxide metabolites.</p><p>&nbsp;</p><p>The presentation of mirtazapine is as a racemate. &nbsp;It is not known whether first pass extraction of the drug is stereoselective but it is known that the clearance of the two enantiomers is by different metabolic processes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Mirtazapine is extensively metabolised and its metabolites are eliminated via the urine and faeces within four days. Major pathways of biotransformation are demethylation and oxidation, followed by conjugation. &nbsp;The demethyl metabolite is pharmacologically active and appears to have the same pharmacokinetic profile as the parent compound.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><strong>Renal and/or Hepatic Impairment</strong></p><p>The clearance of mirtazapine may be decreased as a result of renal or hepatic insufficiency. Mirtazapine is substantially excreted by the kidney (75%) and the risk of decreased clearance of this drug is greater in patients with impaired renal function, refer to DOSAGE AND ADMINISTRATION.</p><p>&nbsp;</p><p><strong>Geriatric</strong></p><p>The recommended dosage regimen is the same as for adults. &nbsp;Increases should be monitored carefully (see DOSAGE AND ADMINISTRATION).</p><p>&nbsp;</p><p><strong>Children and Adolescents</strong></p><p>The safety and effectiveness of mirtazapine had not been established in children and adolescents and therefore should not be prescribed in these patients groups (see WARNINGS AND PRECAUTIONS).</p><p>&nbsp;</p><p><strong>Sex</strong></p><p>The half-life elimination of mirtazapine ranged from 20&ndash;40 hours, longer half-lives up to 65 hours have occasionally been recorded and shorter half-lives have been seen in young men.</p><p>&nbsp;</p><p><strong>Race</strong></p><p>There is no information available regarding the effect of race on the pharmacokinetics of mirtazapine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Most of the toxicity studies conducted in animals did not incorporate measurements of exposure, allowing only a limited assessment of the potential risk to humans at anticipated clinical exposures. Repeat dose toxicity studies in dogs found CNS excitation, increased hepatic enzymes and histopathological changes in the liver associated with the induction of microsomal enzymes, at systemic exposure levels comparable to those expected in humans. &nbsp;Repeat dose studies in rats also showed hepatic cell hypertrophy at these systemic exposure levels. &nbsp;The relevance of these toxicological models for the assessment of possible human toxicity is uncertain. &nbsp;During the drug&#39;s clinical development, elevation of hepatic transaminase activities was noted (see UNDESIRABLE EFFECTS).</p><p>&nbsp;</p><p>Long term post-marketing data are not yet available.</p><p>Refer also to the section WARNINGS AND PRECAUTIONS; <strong>Carcinogenesis, Mutagenesis, Impairment of Fertility.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lactose Monohydrate</p></td></tr><tr><td style="vertical-align:top"><p>Microcrystalline cellulose M102</p></td></tr><tr><td style="vertical-align:top"><p>Croscarmellose Sodium</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Methylcellulose 2910 E5</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Cellulose (LF)</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene Glycol 8000</p></td></tr><tr><td style="vertical-align:top"><p>Titanium Dioxide</p></td></tr><tr><td style="vertical-align:top"><p>Red Iron Oxide (30 mg tablets)</p></td></tr><tr><td style="vertical-align:top"><p>Yellow Iron Oxide (30 mg &amp; 15 mg) tablets</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Store in original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong></p><p>Blister: Film PVC/PVdC Clear 10 MIL 205/60 205MM Foil Silver Plain 205MM 25&micro;M</p><p>&nbsp;</p><p><strong>Secondary packaging:</strong></p><p>Carton</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., 150 Signet Drive Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>